AlphaLISA SureFire Ultra Human Phospho-Tau Thr217 Detection Kit, 50,000 Assay Points

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

AlphaLISA SureFire Ultra Human Phospho-Tau Thr217 Detection Kit, 50,000 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human Phospho-Tau (Thr217) assay is a sandwich immunoassay for quantitative detection of phospho-Tau in cellular lysates using Alpha technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

View product information

Feature	Specification
Application	Cell Signaling
Sample Volume	10 µL

Request More Information

The AlphaLISA™ SureFire® Ultra™ Human Phospho-Tau (Thr217) assay is a sandwich immunoassay for quantitative detection of phospho-Tau in cellular lysates using Alpha technology.

View product information

Product Variants

Unit Size: 100 Assay Points

Part #:

ALSU-PTAU-G-HV

List Price

USD 694.00

Unit Size: 500 Assay Points

Part #:

ALSU-PTAU-G500

List Price

USD 2,346.00

Unit Size: 10,000 Assay Points

Part #:

ALSU-PTAU-G10K

List Price

USD 14,270.00

Unit Size: 50,000 Assay Points

Part #:

ALSU-PTAU-G50K

List Price

USD 46,060.00

Product information

Overview

Tau proteins, derived from tubulin-associated units, play a pivotal role in the pathogenesis of Alzheimer’s disease (AD). Hyperphosphorylated Tau aggregates form filaments, which can further condense into neurofibrillary tangles. These Tau aggregates, often referred to as ‘seeds,’ can propagate pathology from cell to cell, similar to prion transmission. Effective therapeutic strategies for AD include medications that modulate Tau hyperphosphorylation and reduce Tau aggregation.

The AlphaLISA SureFire Ultra Human Phospho-Tau (Thr217) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-Tau in cellular lysates, using Alpha technology.

Formats:

The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

Cell and tissue lysates
Antibody modulators
Biotherapeutic antibodies

Alpha SureFire kits can be used for:

Cellular kinase assays
Receptor activation studies
High-throughput drug screening

Specifications

Other Specifications

Application	Cell Signaling
Automation Compatible	Yes
Brand	AlphaLISA SureFire Ultra
Detection Modality	Alpha
Host Species	Human
Lysis Buffer Compatibility	Lysis Buffer
Molecular Modification	Phosphorylation
Product Group	Kit
Sample Volume	10 µL
Shipping Conditions	Shipped in Blue Ice
Target	Tau
Target Class	Phosphoproteins
Target Species	Human
Technology	Alpha
Therapeutic Area	Neuroscience
Unit Size	50,000 Assay Points

Assay validation

Inhibition of phospho-Tau (Thr217) in endogenous cellular models

MCF7 cells were seeded in a 96-well plate(40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated for 6 hours with increasing concentrations of Staurosporine prepared in media containing 1% FBS. After treatment, the cells were lysed with 100 µL of lysis buffer for 10 minutes at RT with shaking (350 rpm). Tau Phospho(Thr217) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision Nexus™ using standard AlphaLISA settings.

As expected, Staurosporine (a broad-spectrum protein kinase inhibitor) triggered a dose-dependent decrease in the levels of Phospho-Tau (Thr217).

Inhibition of phospho-Tau (Thr217) in endogenous cellular models

SH-SY5Y cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated for 96 hours at 37°C, 5% CO2. The cells were treated for 6 hours with increasing concentrations of Staurosporine prepared in media containing 1% FBS.

After treatment, the cells were lysed with 100 µL of lysis buffer for 10 minutes at RT with shaking (350 rpm). Tau Phospho(Thr217) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision Nexus using standard AlphaLISA settings.